Rekvina Laboratories accepted the resignation of Deepak Khandelwal from his roles as Company Secretary and Compliance Officer. The departure is effective September 2, 2026.

The company disclosed the change to BSE Limited in compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Khandelwal cited personal reasons for his exit.

Resignation Details

Khandelwal submitted his resignation letter on September 2, 2026, stating that he would cease duties at the close of business hours on the same day. He requested the company to process outstanding salary dues and provide a service certificate for his tenure.

The company confirmed receipt of the resignation and initiated necessary statutory formalities. Khandelwal agreed to cooperate with the handover of records and documents under his responsibility.

Rekvina Laboratories Limited has completed the acquisition of Radiant Parenterals Limited, making the latter a wholly owned subsidiary. The Board of Directors approved the allotment of 50,87,750 equity shares on a preferential basis during its meeting held on August 12, 2026. The move aims to consolidate operations within the pharmaceutical sector, leveraging shared resources and distribution networks to expand market presence.

The acquisition was executed through two distinct preferential allotments. The primary component involved a share swap valued at ₹4,62,77,500, where Rekvina issued 46,27,750 equity shares at an issue price of ₹10 per share (including a premium of ₹5) to existing shareholders of Radiant. This transaction transferred 100% of Radiant’s equity share capital, comprising 18,51,100 shares of face value ₹10 each, from five sellers including Surbhit Mukesh Shah and Amit Mukesh Shah.

Additionally, the company allotted 4,60,000 equity shares for cash consideration totaling ₹46,00,000. These shares were issued to non-promoter investors Amitkumar Arunkumar Rao and his HUF at the same issue price of ₹10 per share. All securities allotted in this preferential issue are subject to lock-in restrictions as prescribed under Chapter V of the SEBI ICDR Regulations, 2018.

What the Numbers Show

Radiant Parenterals demonstrated significant revenue growth prior to the acquisition, reporting revenue of ₹31,67,12,500 in FY25 compared to ₹17,36,40,660 in FY24. This represents an increase of over 82% year-on-year, indicating strong operational momentum before being integrated into Rekvina’s portfolio. The target entity, engaged in manufacturing injectables and syrups, is WHO-GMP and ISO 9001-2015 certified.

Shareholding Pattern Changes

The preferential allotment significantly altered the shareholding structure of key investors. Surbhit Mukesh Shah’s stake increased from 15.22% to 22.26%, while Amit Mukesh Shah’s holding rose from 13.73% to 27.07%. New investors Dhruvalkumar Patel, Krima Surbhit Shah, and Ami Amit Shah acquired stakes of 2.00%, 3.00%, and 3.00% respectively through the share swap mechanism.

The cash component of the issue saw Amitkumar Arunkumar Rao increase his holding from 1.65% to 4.49%, while his HUF stake adjusted from 4.72% to 3.10%. The total number of investors participating in the preferential issue was seven, comprising five shareholders in the swap transaction and two in the cash transaction.